Spero Therapeutics (SPRO) Insider Deshpande Buys 20,000 Shares

Milind Deshpande made a notable move by buying 20,000 shares of Spero Therapeutics, Inc. (NasdaqGS: SPRO) on June 23, 2026. This insider transaction was not part of a pre-planned trading scheme, highlighting a direct investment in the company's future.

Insider Buying and Selling at Spero Therapeutics, Inc.

On June 23, 2026, several insiders, including Milind Deshpande, purchased shares of Spero Therapeutics. Milind Deshpande, along with Jackson Scott Thomas, John Pottage Jr., Cynthia Smith, Patrick V.J.J. Vink, and Frank Thomas, each acquired 20,000 shares. These purchases were made outside of any pre-planned trading programs.

Spero Therapeutics, Inc. Stock Up 78.8%

Shares of Spero Therapeutics were trading near $2.02 on Friday. The company, with a market cap of about $116.9 million, has a P/E ratio of 7.48, indicating a relatively low valuation compared to its earnings. Over the past year, the stock has ranged from a low of $1.80 to a high of $3.22, with a 50-day moving average of $2.63 and a 200-day moving average of $2.40. Spero's financial health is underscored by a strong current ratio of 10.50 and a quick ratio of 10.23, though it carries a debt-to-equity ratio of 4.67.

Analysts Set New Price Targets

Analysts have shown interest in Spero Therapeutics, with HC Wainwright & Co. maintaining a 'buy' rating and setting a price target of $5.00 on January 30, 2025. The consensus among analysts is a 'hold' recommendation, with an average target price of $4.00.

About Spero Therapeutics

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing new treatments for multi-drug resistant bacterial infections and rare diseases. Headquartered in Cambridge, Massachusetts, the company is led by CEO Esther P. Rajavelu and employs around 25 people. Spero's leading product candidate, Tebipenem HBr, is an oral antibiotic aimed at treating complicated urinary tract infections. The company has strategic partnerships for the development and commercialization of its products in various international markets.

Bottom Line

Milind Deshpande's recent share purchase signals confidence in Spero Therapeutics' potential. Investors often monitor such insider activities for insights into a company's prospects. However, it's important to remember that insider transactions are just one piece of the puzzle. Spero's stock performance and analyst ratings provide additional context for evaluating its market position.